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Abstract
Background: In early clinical studies, the live tuberculosis vaccine Mycobacterium bovis BCG exhibited 80% protective
efficacy against pulmonary tuberculosis (TB). Although BCG still exhibits reliable protection against TB meningitis and
miliary TB in early childhood it has become less reliable in protecting against pulmonary TB. During decades of in vitro
cultivation BCG not only lost some genes due to deletions of regions of the chromosome but also underwent gene
duplication and other mutations resulting in increased antioxidant production.
Methodology/Principal Findings: To determine whether microbial antioxidants influence vaccine immunogenicity, we
eliminated duplicated alleles encoding the oxidative stress sigma factor SigH in BCG Tice and reduced the activity and
secretion of iron co-factored superoxide dismutase. We then used assays of gene expression and flow cytometry with
intracellular cytokine staining to compare BCG-specific immune responses in mice after vaccination with BCG Tice or the
modified BCG vaccine. Compared to BCG, the modified vaccine induced greater IL-12p40, RANTES, and IL-21 mRNA in the
spleens of mice at three days post-immunization, more cytokine-producing CD8+ lymphocytes at the peak of the primary
immune response, and more IL-2-producing CD4+ lymphocytes during the memory phase. The modified vaccine also
induced stronger secondary CD4+ lymphocyte responses and greater clearance of challenge bacilli.
Conclusions/Significance: We conclude that antioxidants produced by BCG suppress host immune responses. These
findings challenge the hypothesis that the failure of extensively cultivated BCG vaccines to prevent pulmonary tuberculosis
is due to over-attenuation and suggest instead a new model in which BCG evolved to produce more immunity-suppressing
antioxidants. By targeting these antioxidants it may be possible to restore BCG’s ability to protect against pulmonary TB.
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Introduction
Oxidants fulfill signaling roles during the activation of innate
immune responses and promote the development of adaptive
immunity [1–3]. Growing evidence implicates microbial antiox-
idants in the suppression of host immune responses to Mycobac-
terium tuberculosis. The iron co-factored superoxide dismutase
(SodA) and its secretion channel, SecA2, suppress macrophage
activation in vitro and inflammatory and immune responses in
vivo [4–6]. An extracytoplasmic-function sigma factor, SigH,
controls the expression of several antioxidants including thior-
edoxin and is associated with lung immunopathology [7–9]. Other
antioxidants including catalase-peroxidase, alkylhydroperoxidase
C, and the NADPH quinone reductase Rv3303c also contribute to
mycobacterial virulence [10–12].
The current vaccine against tuberculosis (TB), the bacillus of
Calmette and Gue ´rin (BCG), also secretes large amounts of
antioxidants. BCG is widely administered however it has failed to
control the enormous global burden of TB that causes about 9
million new active cases and 1.7 million deaths annually [13–16].
BCG is a live vaccine derived from M. bovis via the loss of RD1, the
‘‘region of deletion 1’’ that encodes the ESX-1 secretion system
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th century
BCG was sent to investigators throughout the world and
maintained by serial passage, i.e., by transferring a portion of an
aging culture into fresh media. Over decades this practice
produced multiple BCG daughter strains with additional regions
of genomic deletion as well as regions of genomic duplication and
other mutations [17–19]. These substrains represent divergent
evolution from the original BCG and some have been transferred
over 1500 times [17]. Some BCG daughter strains exhibit genomic
duplication of sigH, trxC (thioredoxin), trxB2 (thioredoxin reduc-
tase), whiB1, whiB7, and lpdA (Rv3303c) as well as increased
expression of genes encoding other antioxidants including SodA,
thiol peroxidase, alkylhydroperoxidases C and D, and other
members of the whiB family of thioredoxin-like protein disulfide
reductases [17,19–21].
Although attenuated from the loss of RD1, some BCG
substrains exhibit potent immune suppressive properties. BCG
inhibits phagolysosomal fusion in macrophages [22], reduces
monocyte apoptosis [23], down-regulates MHC class II molecules
[24], and suppresses the maturation of dendritic cells [25]. The
immune suppressive capacity of BCG is perhaps most apparent in
vivo. Some BCG daughter strains persist indefinitely in small
animals [4,26–28], induce lung pathology [4,29], and cause death
when administered as a large dose [30]. In man, the rising
prevalence of HIV infection and virulence attributes of BCG have
raised concerns about disseminated BCG infection after routine
neonatal vaccination and it is estimated that more than 2000
serious complications of BCG vaccination occur annually [31].
To test the hypothesis that the duplication of SigH and
production of SodA contribute to the immune suppressive capacity
of BCG, we modified an extensively cultivated BCG daughter
strain to eliminate both copies of sigH and to reduce the activity
and secretion of SodA. The modified vaccine induced stronger
immune responses than the parent BCG vaccine during primary
vaccination as well as enhanced recall immune responses upon
subsequent challenge. These observations have important impli-
cations for efforts to develop a more effective live vaccine against
TB. They further suggest the novel hypothesis that the extensively
cultivated BCG daughter strains are immune suppressive as a
consequence of increased antioxidant production. This contrasts
with the theory that the extensively cultivated BCG daughter
strains are over-attenuated although both theories attempt to
explain the apparent decline in efficacy of BCG against pulmonary
TB during decades of cultivation in vitro [32,33]. Finally, the
findings highlight the importance of host-generated oxidants in the
development of adaptive immunity.
Results
Construction and in vitro characterization of 3dBCG, a
modified BCG vaccine
We used allelic inactivation to eliminate secA2 and sigH in BCG
Tice, and dominant-negative (dn) interference techniques to
reduce the activity of SodA. To construct BCGDsecA2DsigH
(‘‘double-deletion BCG’’, ‘‘DDBCG’’) secA2 and sigH were
inactivated in sequence (Fig. 1A). During attempts to inactivate
sigH with a hygromycin-resistance (hygR) cassette we found that
only about 15% of colonies lacked sigH whereas most colonies
contained an intact sigH along with DNA restriction fragments
suggesting successful interruption of sigH by the hygR allele. This
finding is consistent with reports that most BCG daughter strains
have two copies of sigH due to tandem duplication of the region of
chromosomal DNA containing sigH [17,19].
After verifying that sigH was absent from the colony selected for
further modification, we inserted an allele encoding a dominant-
negative mutant of SodA into the chromosome of DDBCG to
yield 3dBCG (BCGDsecA2DsigHdnSodA). SodA contains histidines
that chelate the active-site iron [34] and we eliminated H28 and
H76 to produce an inactive SodA mutant. Enzyme activity assays
(Fig. 1B) and immunoblotting (Fig. 1C) demonstrated a
dominant-negative effect with reduced enzyme activity in 3dBCG
compared to DDBCG despite comparable amounts of SodA
protein, presumably because DH28DH76 monomers were incor-
porated into the tetrameric, functional form of SodA and inhibited
enzyme activity. Compared to BCG, the inactivation of secA2 in
DDBCG nearly eliminated SodA secretion however enzyme
Figure 1. Construction of modified BCG vaccines. (A) Southern hybridization demonstrating inactivation of secA2 and sigH. DraIII-digested DNA
from each strain was probed for secA2, sigH and the hygR cassette used to inactivate sigH. Lane 1, BCG Tice; lane 2, BCGDsecA2; lane 3, BCGDsigH; lane
4, BCGDsecA2DsigH (DDBCG); lane 5, a colony of BCGDsecA2 with only one copy of sigH inactivated. secA2 contains two internal DraIII sites and DraIII-
digested DNA was predicted to yield fragments of 307 bp, 785 bp, and 10,544 bp. sigH was predicted to be on a 2895 bp fragment. The hygR
cassette contains an internal DraIII site and was predicted to yield 2938 bp and 1612 bp fragments after inactivation of sigH. (B) Differences in the
localization and activity of SodA in BCG, DDBCG, and 3dBCG. A representative experiment shows the SOD units per ml of concentrated supernatant
or lysate. (C) Immunoblot showing comparable amounts of SodA in lysates of DDBCG (lane 1) and 3dBCG (lane 2), despite the marked difference in
SOD activity as shown in (b).
doi:10.1371/journal.pone.0005531.g001
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exhibited a 95% reduction in enzyme activity. In summary, we
introduced three modifications into BCG to reduce antioxidant
production, yielding 3dBCG.
3dBCG induces stronger recall T cell responses
Most vaccines are administered to generate memory lymphocytes
that can proliferate rapidly, thereby accelerating the kinetics and
magnitude of immune responses to a subsequent infection. To
determine whether vaccination with 3dBCG or BCG induce recall
immune responses, we immunized C57Bl/6 mice subcutaneously
with BCG, 3dBCG, or sterile media (control vaccination group).
BCG typically can be recovered months after inoculation of C57Bl/
6 mice depending upon the substrain, dose, and route of
administration [4,26,27], however BCG-induced T cell responses
decline rapidly almost to pre-vaccination levels within a few months
of treating vaccinated mice with antibiotics [35]. Thus, to assess
recall immunity without interference from persisting vaccine bacilli,
wetreatedthevaccinatedgroupsofmicewithisoniazidand rifampin
from day 30 to day 60 post-vaccination and this reduced the spleen
titer of vaccine bacilli to below the lower limits of detection
(50 CFU). After resting the mice for an additional 2 to 9 weeks, they
were challenged intravenously with 2610
7 CFU of BCG Tice.
Recall immunity was evaluated on days 26 to 30 post-challenge
by incubating splenocytes on uninfected and BCG-infected bone
marrow-derived macrophages (BMDMs). Antigen-specific cytokine
production, quantified by intracellular cytokine staining and flow
cytometry (Fig. 2A), was reported as the number of cytokine+ T
cells per spleen. The magnitude of the CD4+ IFN-c T cell response
following challenge in BCG-vaccinated mice (median 67,560/
spleen) was not significantly greater than in media-vaccinated
control mice (median 43,300/spleen) undergoing a primary
response to the BCG challenge (Fig. 2B). In contrast, more IFN-
c+ CD4+ T cells were present in 3dBCG-vaccinated mice (median
138,500/spleen). The number of CD4+ lymphocytes producing
TNF-a or both IFN-c and TNF-a was also greater in 3dBCG-
vaccinated mice than in BCG-vaccinated or control mice.
The production of IL-2 is associated with multi-functional, high-
quality memory T cells [36] and thus as a secondary endpoint we
also evaluated the IL-2 recall response. The number of IL-2+ and
IFN-c+IL-2+ (double-positive) CD4+ T cells in BCG-vaccinated
mice was not significantly greater than the response of control
mice (Fig. 2B). In contrast, more IL-2+ and IFN-c+IL-2+ CD4+
T cells were present in 3dBCG-vaccinated mice than in control
mice. For the comparisons involving 3dBCG- and BCG-
vaccinated mice, there was a trend towards statistical significance
(P.0.05, ,0.1). The numbers of IFN-c- or TNF-a-producing
CD8+ T cells in the spleen were low at day 26 to 30 post-challenge
(data not shown) compared to the number of CD4+ T cells
producing these cytokines. However, five of nine 3dBCG-
vaccinated mice exhibited greater than 10,000 IL-2+ CD8+ T
cells in the spleen compared to none of seven media-vaccinated
mice (P=0.03, Fisher’s exact, two-tailed) and one of nine BCG-
vaccinated mice.
After noticing higher cytokine production in re-stimulated
splenocytes of 3dBCG-vaccinated mice in the first experiment, we
enumerated challenge bacilli in spleens of mice in subsequent
experiments and thus determined post-challenge CFU values for six
vaccinated mice per group. Fewer bacilli of the BCG challenge dose
were found in the spleens of 3dBCG-vaccinated mice than in BCG-
vaccinated mice (median Log10 CFU of 5.05 and 5.80, respectively,
P=0.034) or media-vaccinated mice (median Log10 CFU 5.95,
P=0.013) (Fig. 3A). An inverse correlation between median CFU
and median CD4+ IFN-c T cell responses from each of the three
vaccinated groups was observed (R
2=0.99) (Fig. 3B), indicating
that the stronger 3dBCG-induced recall CD4+ IFN-c responses
were associated with better clearance of the challenge bacilli.
Therefore, under circumstances in which the live vaccine strain is
not allowed to persist, prior vaccination with 3dBCG enhanced
BCG-specific immune responses post-challenge and reduced the
number of challenge bacilli, whereas prior vaccination with BCG
did not confer much advantage over unvaccinated mice.
3dBCG induces stronger CD8+ T cell responses during
primary vaccination
Results from the recall immune response experiments above led
us to evaluate primary T cell responses in more detail. We used
Balb/c mice to track peptide-specific responses to immunodomi-
nant epitopes including TB10.474-88 - ST15, a CD4 epitope [37],
and TB10.3/10.420-28 - GL9, a CD8 epitope [38]. Preliminary
experiments showed comparable numbers of cytokine-producing
CD4+ T cells in mice vaccinated subcutaneously and intrave-
nously, however the intravenous group demonstrated greater
CD8+ T cell responses by flow cytometry (data not shown). Thus,
to determine the kinetics and peak of the primary response we
inoculated Balb/c mice intravenously with 5610
5 CFU of BCG or
3dBCG and analyzed the number of IFN-c-producing CD8+ and
CD4+ T cells at 8, 9, 12, 17 and 30 days post-inoculation. The
CD8+ T cell response to peptide GL9 peaked at day 9 post-
inoculation (Fig. 4A) and the CD4+ T cell response to peptide
ST15 peaked at day 12 (Fig. 4B). The kinetics of the T cell
responses to BCG and 3dBCG vaccination were similar however
vaccination with 3dBCG induced higher peak IFN-c+, IFN-
c+TNF-a+ and IFN-c+IL-2+ CD8+ T cell responses to GL9 than
vaccination with BCG (Fig. 4C).
3dBCG induces more IL-2-producing CD4+ T cells
The presence of IL-2 during the contraction phase of the
primary immune response is critical for the development of
memory T cells that can subsequently proliferate to provide a
recall T cell response [36,39,40]. The kinetics of the immune
response after subcutaneous vaccination of Balb/c mice with
5610
5 CFU of BCG or 3dBCG demonstrated declines in the
number of IFN-c+ CD4+ T cells and increases in the number of
IL-2+ CD4+ T cells in response to peptide ST15 from day 17 to
day 30 post-vaccination (Fig. 5A,B). The number of ST15-
specific IFN-c- or TNF-a-producing CD4+ T cells at the peak
(day 17) or memory phase (day 30) CD4+ T cell response were
similar in the BCG and 3dBCG groups. In contrast, vaccination
with 3dBCG induced more ST15-specific IL-2+ CD4+ T cells
during the memory phase (median 18,400/spleen) than vaccina-
tion with BCG (median 10,760/spleen) (Fig. 5C). The higher
ratio of IL-2+ to IFN-c+ CD4+ T cells in 3dBCG-vaccinated mice
compared to BCG-vaccinated mice may have contributed to the
greater recall immune response in 3dBCG-vaccinated mice during
subsequent challenge.
3dBCG induces greater early expression of IL-12p40,
RANTES, and IL-21 mRNA
The cytokine milieu after vaccination influences the differenti-
ation and polarization of naı ¨ve CD4+ T cells. IFN-c, IL-12, and
RANTES (CCL5) promote a Th1 response, IL-4 a Th2 response,
IL-6 a Th17 response, and IL-21 a Tfh (T follicular helper)
response [41–44]. To determine whether BCG and 3dBCG
induce different patterns of expression of cytokines that may
explain some of the differences in adaptive immunity reported
above, we inoculated C57Bl/6 mice intravenously with
BCG Antioxidants Foil Immunity
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7 CFU of BCG, 3dBCG, or PBS (control). Spleens were
harvested 72 hours later and the mRNA from whole spleens was
evaluated by RT-PCR for these Th-polarizing cytokines. BCG-
and 3dBCG-vaccinated mice exhibited increased expression of
IFN-c, IL-12p40, IL-6, and IL-21 compared to control mice
(Fig. 6) whereas the expression of IL-4 was not significantly
different in either vaccinated group or controls. The expression of
some genes was significantly greater in 3dBCG- than BCG-
vaccinated mice including 33% more IL-12p40 (IL-12b), 34%
more IL-21, and 30% more RANTES, which was suppressed in
BCG-vaccinated mice compared to the control and 3dBCG
groups. In summary, within three days of inoculation, BCG and
3dBCG induce different patterns of expression of immune
response genes likely to influence subsequent T cell responses.
Figure 2. Cytokine-producing CD4+ T-cells in the spleens of vaccinated mice after intravenous challenge. (A) Representative plots
show IFN-c+, TNF-a+ and IFN-c+TNF-a double-positive cytokine production by splenocytes of mice vaccinated subcutaneously with BCG or 3dBCG at
28 days after intravenous challenge with 2610
7 CFU of BCG. Splenocytes were re-stimulated on IFN-c-treated uninfected bone-marrow derived
macrophages and BCG-infected macrophages. Percent values represent frequency of cytokine+ CD4+ T cells for each stimulation condition. (B)
Number of IFN-c+, TNF-a+, IL-2+ and dual cytokine+ CD4+ T cells in spleens 26 to 30 days after intravenous challenge with BCG. Each data point
represents the number of BCG-specific cytokine+ T cells in one mouse spleen, calculated from percent values of cytokine+ CD4+ T cells, as in (a), and
total number of splenocytes isolated from each mouse. The bars represent median values from 7 to 9 mice in each vaccinated group. Media/- mice
are age-matched controls that were vaccinated with media but not challenged, C=challenged. The variances of the median values of the three
challenged groups were compared by the Kruskal-Wallis non-parametric test: IFN-c, P=0.0031; TNF-a, P=0.0006; IL-2, P=0.0165; IFN-c+TNF-a,
P=0.0007; and IFN-c+IL-2, P=.0131. The Mann-Whitney P values for two group comparisons are displayed in the figure.
doi:10.1371/journal.pone.0005531.g002
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forming units (CFU) persisting in the spleens of mice on day 26–30 after intravenous challenge with 2610
7 CFU of BCG. Data are from six mice per
group from two experiments. Individual and median values are displayed. The variance of the medians of the three groups was significant, P=0.0186,
Kruskal-Wallis test. Mann-Whitney P values for two-group comparisons are shown in the figure. (B) Plot of median Log10 CFU in spleens of vaccinated
mice versus the median CD4+ IFN-c responses for the three vaccination arms. Coefficient of correlation, R
2 was calculated using median values from
each vaccination group.
doi:10.1371/journal.pone.0005531.g003
Figure 4. Kinetics of the primary immune response and peak CD8+ T cell responses. (A) Numbers of IFN-c+ CD8+ T-cells in spleens after
re-stimulation with TB10.3/10.420-28 peptide (GL9) at 8, 9, 12, 17 and 30 days after intravenous inoculation of media, BCG or 3dBCG. The symbols and
error bars represent median and range of responses of 3 to 9 mice per time point. (B) Numbers of IFN-c+ CD4+ T cells in spleens after re-stimulation
with TB10.474-88 peptide (ST15) on days after vaccination. (C) Numbers of IFN-c+, and IFN-c+TNF-a+, and IFN-c+IL-2+ CD8+ T cells in spleens after re-
stimulation with TB10.3/10.420-28 peptide - GL9 at the peak of the primary CD8+ T cell response (day 9 post-inoculation). Each symbol represents the
number of cytokine-producing CD8+ T cells from one mouse. The bars represent median values for each group and Mann-Whitney P values for two-
group comparisons are displayed in the figure. The variances of the medians of the three groups were significant: IFN-c, P=0.0009; IFN-c+TNF-a,
P=0.0013; and IFN-c+IL-2, P=0.0415, Kruskal-Wallis test.
doi:10.1371/journal.pone.0005531.g004
BCG Antioxidants Foil Immunity
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e55313dBCG grows slower in vitro and persists less well in vivo
We have previously reported that under culture conditions
wherein a detergent (e.g., Tween 80) is used to reduce the
clumping of bacterial cells, antisense mutants of M. tuberculosis
H37Rv with diminished production of SodA grow slower than the
parent H37Rv strain [4]. Furthermore, these SodA mutants are
attenuated in their ability to cause death and to persist in vivo [4].
Attenuation has also been reported for secA2 deletion mutants of
M. tuberculosis [5]. To determine whether the multiple mutations in
antioxidant production introduced into BCG similarly affects in
vitro growth and in vivo persistence, we monitored the
absorbance of broth cultures of BCG and 3dBCG over time
and compared the number of viable bacilli in the spleens of Balb/
C at four weeks after intravenous inoculation. Relative to BCG,
3dBCG exhibited about 30% less of an increase in absorbance
over ten days of cultivation (Fig. 7A), indicating a modest
reduction in its rate of growth. Furthermore, the number of
3dBCG recovered from the spleens of mice was reduced 32-fold
compared to BCG (Fig. 7B). The recovered bacilli represented
1.8 percent and 58.6 percent, respectively, of the number of bacilli
inoculated (P=.027, two-sample T test). Thus, the stronger
immune responses induced by 3dBCG compared to BCG as
demonstrated above cannot be attributed to an effect of higher
numbers of persisting vaccine bacilli. Instead the reduced
persistence of 3dBCG in vivo is a consequence of the stronger
immune responses induced by 3dBCG along with its slower rate of
growth.
Discussion
The capacity of M. tuberculosis and M. bovis to secrete multiple
antioxidants may have evolved to enable growth under aerobic
conditions by reducing oxidative damage to cell wall lipids and
proteins, which comprise nearly 40 per cent of the dry weight of
mycobacteria. However, beyond their role in microbial physiol-
ogy, the production and secretion of large amounts of antioxidants
gives the bacterium obvious advantages within mammalian hosts.
Although best known for their microbicidal properties, oxidants
produced by immune cells also help to coordinate the host
response to infection. Oxidants have important signaling roles in
the activation and apoptosis of macrophages [1], the maturation of
dendritic cells [2], and the proliferation of T cells [3]. Chronic
granulomatous disease (CGD), a genetic disease in which the
phagocyte oxidase fails to assemble and produce superoxide,
causes defects in signaling cascades that impair phagocyte
activation [45], antigen presentation [46], and the development
of memory lymphocytes [47]. By analogy, M. tuberculosis secretion
of SodA, an enzyme that inactivates superoxide, may induce a
similar albeit localized deficiency of superoxide that inhibits the
development of adaptive immunity, resulting in chronic infection
rather than eradication of the pathogen. Granulomatous pathol-
ogy is a hallmark of both CGD and TB and the pathophysiology
of inflammation in CGD involves impairment of a superoxide-
dependent step in tryptophan metabolism [48]. In summary, the
inactivation of host-generated oxidants by mycobacterial antiox-
idants may disrupt redox signaling during early infection and
Figure 5. Memory CD4+ T cell responses after subcutaneous vaccination with BCG or 3dBCG. Kinetics of (A) IFN-c+ and (B) IL-2+ CD4+ T
cell response in spleens of subcutaneously vaccinated mice in response to TB10.474-88 peptide - ST15 stimulation. The symbols represent median and
range of cytokine responses of 3–7 mice per time point. (C) Numbers of IFN-c+ and IL-2+ CD4+ T cells in spleens and the IL-2+/IFN-c+ ratio of CD4+ T
cells in each spleen after re-stimulation with TB10.474-88 peptide - ST15 at the memory phase of the primary CD4+ T cell response (day 30 post-
vaccination). Each data point represents the number of cytokine+ CD4+ T cells or the ratio from one mouse, with 7 mice per group. The bars
represent median values for each group and Mann-Whitney P values for two-group comparisons are displayed in the figure. The variances of the
medians of the three groups were significant: IFN-c, P=0.0012; and IL-2, P=0.0005, Kruskal-Wallis test.
doi:10.1371/journal.pone.0005531.g005
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5531Figure 6. Expression of genes encoding Th polarizing cytokines. Mice were inoculated by the retro-orbital route and spleens harvested
72 hours later. Each data point represents the level of gene expression by individual mice in each group as determined by RT-PCR and normalized to
the mean value of the PBS-vaccinated group. The bars represent median values for each group and Mann-Whitney P values for two-group
comparisons are displayed in the figure. Statistical comparisons of the variances of the medians of the three groups were: IL-12b, P=0.0006; IFN-c,
P=0.0033; IL-4, P=0.0702; IL-21, P=0.0011; IL-6, P=0.0033; and RANTES, P=0.0112, Kruskal-Wallis test.
doi:10.1371/journal.pone.0005531.g006
Figure 7. In vitro growth and in vivo persistance of BCG and 3dBCG. (A) Plot of the absorbance of cultures of BCG and 3dBCG during ten
days of cultivation. A representative experiment shows A600 values every two days after Middlebrook 7H9 media containing Tween 80 in roller bottles
was seeded with BCG or 3dBCG. The initial inoculum was adjusted to an A600 value of 0.2. (B) Spleen CFU at four weeks after intravenous inoculation
of Balb/C mice with BCG or 3dBCG. Inocula were prepared based on absorbance values and then titered to determine the number of viable bacilli
administered to each group of three mice – 6.6610
6 CFU for BCG; 7.7610
6 CFU for 3dBCG. The numbers represent the weights of the spleens in
grams.
doi:10.1371/journal.pone.0005531.g007
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and promoting tissue-damaging immunopathology.
By reducing antioxidant activity and secretion in BCG to yield
3dBCG, we unmasked immune responses during vaccination with
3dBCG that were suppressed by the parent BCG vaccine.
Enhanced cytokine responses were detected within 3 days of
vaccination. These differences may have clinical relevance as IL-
12 and RANTES contribute to protection against TB in man
[49,50]. The early differences in cytokine responses were followed
by differences in T cell responses. IL-12 and RANTES augment
Th1 responses [41,42] and IL-21 and IL-12 promote the
expansion of CD8+ T cells [51,52]. Thus the greater expression
of IL-12p40, RANTES and IL-21 observed on day 3 post-
vaccination in the 3dBCG group may have contributed to stronger
antigen-specific IL-2+ production by CD4+ T cells as well as
stronger CD8+ T cell responses. The enhanced CD8+ responses in
3dBCG-vaccinated mice may also have clinical relevance as CD8+
T cells contribute to protection against pulmonary TB in man
[53,54]. In effect, the modifications to BCG correct a deficiency in
vaccine immunogenicity that may partly be responsible for the
suboptimal efficacy of BCG against pulmonary TB.
Another deficiency of some current BCG vaccines is the poor
induction of immune memory. The duration of protection
conferred by vaccination with BCG in mice appears to be limited
to the time that BCG persists in vivo [35]. However, persisting live
vaccine bacilli represent a risk for disseminated BCG infection,
especially in persons infected with HIV [31]. Thus, modifications
to BCG that promote the development of immune memory and
confer protection independent of persisting vaccine bacilli should
improve the safety of BCG. In summary, the differences in the
immune responses of 3dBCG- and BCG-vaccinated mice suggest
that reducing the activity and secretion of microbial antioxidants
in BCG leads to greater activation of innate immunity, stronger
antigen-specific T cell responses, and better memory immunity.
We suspect there are also other differences in response to these
vaccines and this is a focus of ongoing investigation.
The enhanced immunogenicity of 3dBCG compared to BCG
challenges the hypothesis that extensively cultivated BCG
daughter strains are over-attenuated [32,33]. To briefly review
the background of the over-attenuation hypothesis and its
influence on BCG vaccination practices, as early as the late
1940s concerns were raised about the possible over-attenuation of
BCG [55]. The context was the observation of highly variable
protection, from 0% to 80%, against pulmonary TB in human
studies of BCG vaccination [13,14]. Furthermore, investigations in
mice indicated that BCG daughter strains differed in their ability
to persist in vivo and to confer protection against challenge by
virulent M. tuberculosis [27,56,57]. Indeed, protection in mice
correlated directly with the invasiveness and persistence of the
BCG daughter strain [57]. Such observations, along with the
assumption that virulence would be lost rather than gained during
cultivation in vitro, led to the conclusion that virulent BCG
substrains should be preferred as they were the most like the
original protective vaccine [30] that had exhibited 80% protective
efficacy against pulmonary TB in uncontrolled studies of nursing
and medical students in the 1920s [58], and also in an early
controlled clinical trial in the 1930s [59].
The opinion that virulent BCG daughter strains were the most
like the original vaccine influenced the selection of the relatively
virulent BCG Danish 1331 and BCG Pasteur 1173P2 vaccines for
the large controlled trial of vaccination with BCG in the
Chingleput region of South India between 1968 and 1971
[13,60,61]. However neither vaccine was effective in persons over
14 years of age. Although this failure is often attributed to a
confounding effect by environmental mycobacteria found in
tropical climates [14], this explanation ignores the fact that in
an earlier trial in the Madanapalle region of South India, only 185
kilometers from Chingleput, BCG exhibited 60% protective
efficacy with an annual rate (per 100,000) of 198 and 79 bacillary
cases, respectively, among controls and BCG vaccinees between
25 and 45 years of age [62]. The protective vaccine used in the
Madanapalle study came from a 1948 subculture of BCG Danish
before it was freeze-dried in 1960 as BCG Danish 1331 [63].
Another clinical trial in the United Kingdom also used BCG
Danish vaccine prepared between 1950 and 1952 to immunize 14
to 15 year-olds, finding a 77% reduction in pulmonary TB [64].
Thus, the clinical data indicate that at one time some BCG
vaccines conferred protection against pulmonary TB in adoles-
cents and adults, including tropical countries with a high
prevalence of TB and environmental mycobacteria. However, as
evidenced by the experience with BCG Danish, something
happened during years of in vitro cultivation to make BCG
become less effective against pulmonary TB. Yet as BCG Pasteur
1173P2 and Danish 1331 are relatively virulent BCG substrains
[27,30,56,61], their failure to protect against pulmonary TB at
Chingleput and in subsequent case-control trials where other less
virulent BCG daughter strains exhibited about 55% protective
efficacy against pulmonary TB [65–67] should not be attributed to
over-attenuation.
Apart from its failure to explain BCG’s unreliable protection
against pulmonary TB, the over-attenuation hypothesis is
inconsistent with the observation that the ‘‘late’’ BCG vaccines
Pasteur 1173P2 and Danish 1331 cause more adverse reactions in
man and exhibit greater virulence in animal models than the
‘‘early’’ BCG Tokyo 172 vaccine strain [14,28,61,68]. Although
the greater virulence of late BCG daughter strains that were
passaged more than 1000 times compared to an early BCG
vaccine passaged only 172 times after it was brought to Japan by
Kiyoshi Shiga in 1924 could be a coincidence of divergent
evolution, observations involving vaccines representing ‘‘linear’’
evolution in the BCG Danish family similarly suggests that over
time BCG became more virulent instead of more attenuated. In
1954, a few years after BCG Danish was the source of vaccine for
the trials in Madanapalle and the United Kingdom in which
protection against pulmonary TB was demonstrated, a freeze-
dried seed lot from the 1077
th transfer of BCG Danish was
preserved as BCG London/Glaxo [63]. Six years later BCG
Danish 1331 was preserved [63]. Yet despite its later derivation,
BCG Danish 1331 is more virulent than BCG London/Glaxo in
animal models. In one study the intraperitoneal injection of a
5 mg dose of Danish 1331 killed male golden hamsters within 100
days whereas more than 50% of hamsters infected with the same
amount of BCG London/Glaxo survived for more than 400 days
[30]. Experiments to determine the minimum ‘‘sensitizing’’ dose,
i.e., the lowest number of bacilli capable of inducing delayed type
hypersensitivity in guinea pigs or bank voles show that it takes only
10 cfu of Danish 1331 compared to about 200 cfu of BCG
London/Glaxo [61,69]. Thus between transfer 1077 and transfer
1331, the BCG Danish family of vaccines became more invasive
and lethal.
When combined with recent reports of the duplication and
increased expression of genes encoding antioxidants in BCG
[17,19], our results suggest a new model to explain how BCG
became more virulent in small animals and less effective in
controlling pulmonary TB in man. Whereas reference isolates of
M. bovis and BCG Tokyo 172 have a single copy of sigH, BCG
Pasteur 1173P2 and Danish 1331 contain bacilli with duplicated
or triplicated sigH [17]. Indeed, BCG Danish appears to be
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or triplication of the DU2-III region of the chromosome that
contains sigH coexist in Danish 1331, only the triplicated form was
found in a BCG Danish strain grown continuously for 1,513
passages [17]. BCG Pasteur 1173P2 also exhibits three-fold higher
expression of sodA than BCG Tokyo 172 and reference M. bovis
[17]. In the context of our findings that SigH and SodA suppress
host immune responses, these mutations suggest a mechanism by
which BCG Pasteur 1173P2 and BCG Danish 1331 evolved to
become more immune suppressive and thus more virulent than
their predecessors. In vitro, a mutation that increases antioxidant
production may benefit BCG by reducing oxidative damage to cell
wall lipids that otherwise would yield aldehydes and other
metabolites that retard growth. Presumably such BCG mutants
could grow faster, and this may explain the increase in oxygen
consumption and growth rate observed over time in the BCG
Danish family [30] and also with BCG Phipps [70]. Our
speculation that these increases in the rate of growth of BCG
during decades of in vitro cultivation partly reflect mutations
resulting in increased antioxidant production is consistent with our
prior report that diminishing the production of SodA reduces the
growth rate of M. tuberculosis [4] as well as our finding in this study
that targeting the production of antioxidants in BCG to yield
3dBCG reduces the rate of growth. The practice of growing BCG
aerobically with detergents to prevent clumping may have
increased oxidant stress to cell wall structures and selected for
increased antioxidant production. Then with each transfer the
bacilli making more antioxidants represented a slightly greater
proportion of the culture until they became dominant. In vivo,
these mutations caused the vaccine to become less potent in
activating host immunity. In effect, we believe that as BCG
evolved it yielded daughter strains with an increased capacity for
suppressing host immune responses.
The model of BCG becoming more immune suppressive may
also provide insight into why the extensively cultivated BCG
daughter strains have remained effective against disseminated TB
while losing their ability to protect against pulmonary TB. As noted
above, 3dBCG was better than the parent BCG vaccine at inducing
CD8+ T cell responses, which may be crucial for killing M.
tuberculosis within macrophages in the lung and thereby limiting the
extent of tissue-damaging granulomatous inflammation. The
immunologic mechanisms for controlling the dissemination of TB
may be different from those needed to prevent lung destruction.
InsteadofrequiringcytotoxicT cells,itseemsthat the dissemination
of infection is controlled primarily with IFN-c-producing CD4+ T
cells that activate macrophages [71]. Paradoxically, clinical data
suggest that the relatively virulent BCG daughter strains may be
slightly more protective against disseminated TB in early childhood
than the relatively immunogenic BCG daughter strains. For
example, fewer cases of disseminated TB occurred in the first two
years of life in children vaccinated with intradermal BCG Danish
1331 than with percutaneous BCG Tokyo 172 [72], despite the
greater immunogenicity of BCG Tokyo [73] and its greater
effectiveness against pulmonary TB [65–67]. The extensively
cultivated BCG substrains persist longer in small animal models
than BCG Tokyo 172 [28,68] and in both mice and man persisting
vaccine bacilli may help to maintain a population of IFN-c-
producing CD4+ T cells that can respond immediately to infection
withM. tuberculosisto form granulomas and reducedissemination. In
contrast, as it typically takes several days for memory CD4+
lymphocytes to begin proliferation upon re-exposure to antigen
[74], if the vaccine strain has mediated its own eradication by
inducing more potent immune responses, there may be a slight
delay in the CD4+ response.
Both early and late BCG daughter strains remain highly
efficacious against TB meningitis and miliary TB in young
children, and it is pulmonary TB that causes the greatest burden of
disease globally [16]. Our results suggest it might be possible to
make improvements in BCG that enhance protection against
pulmonary disease in man. Molecular genetic techniques make it
possible to reduce the activity of antioxidants below the level found
in any BCG vaccine, past or present, and this may enable the
construction of highly immunogenic BCG-derived vaccines that
match or surpass the high protective efficacy against pulmonary
TB observed in early clinical trials. Our findings demonstrate the
value of targeting SigH and SodA in BCG. Other antioxidants
that are more highly expressed in BCG daughter strains than M.
bovis include thiol peroxidase, Rv3303c, and members of the whiB
family of protein disulfide reductases [17]. If these antioxidants
similarly suppress host immune responses they may also be
promising targets for enhancing BCG immunogenicity.
Beyond the implications of these findings for single dose
vaccination with BCG to prevent pulmonary TB, a more
immunogenic BCG should be a better priming vaccine for
subsequent boosting with a heterologous vaccine in accordance
with new TB vaccination strategies [75]. A more immunogenic
BCG also has implications for cancer as increasing host
production of multiple cytokines with anti-tumor activity (i.e., IL-
12p40, RANTES, IL21, and IL-2) has the potential to overcome
some of the limitations of current BCG vaccines as cancer
immunotherapy [76,77]. Finally, BCG occupies a unique place in
the vaccination schedule of infants throughout much of the world.
Thus, a more immunogenic BCG may become a useful vector for
expressing antigens of other pathogens including HIV and
Plasmodium species to produce strong cell-mediated responses,
including CD4+ helper responses, as part of vaccination regimens
against AIDS, malaria, and other infectious diseases.
Materials and Methods
Bacterial isolates, plasmids, media, and growth
conditions
Genetic tools and bacterial isolates are listed in Table S1.
Genetic modifications were made to BCG Tice (Organon Teknika
Corp., Durham, NC). Of note, although historically BCG Tice
was considered to be a weak BCG vaccine that exhibited poor
ability to persist in mice or confer protection against challenge
with M. tuberculosis in mice [27,57], it was reformulated with a
subculture of BCG obtained from the Institut Pasteur in 1951 and
subsequently BCG Tice has exhibited in vivo characteristics
similar to BCG Pasteur 1173P2 [68,78,79].
E. coli strains were grown in LB media. To prepare vaccine
inocula and to compare rates of growth, BCG Tice and modified
strains were grown in roller bottles containing Middlebrook 7H9
media with 10% oleic acid-dextrose-catalase (OADC) enrichment
supplemented with 0.2% glycerol, and 0.05% Tween80. Kana-
mycin (50 mg/ml or 25 mg/ml), apramycin (50 mg/ml), and
hygromycin B (100 mg/ml or 50 mg/ml) were used to select
colonies after genetic manipulations in E. coli or BCG, with higher
concentrations for E. coli and lower concentrations for BCG.
Molecular genetic manipulations
Plasmid and chromosomal integration vectors for allelic
inactivation or expression of dominant-negative monomers of
SodA were electroporated into BCG using standard methods [80].
After electroporation, the strains were incubated in Middlebrook
7H9 media with 5% CO2 at 37uC for 24 hrs before the suspension
was selected on Middlebrook 7H11 agar containing antibiotics as
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unique to the vector.
The inactivation of secA2 was performed using a two-step allelic
exchange strategy with plasmid pMB179, as previously described in
M. tuberculosis [5]. The inactivation of sigH was performed by using
the cosmid-phasmid pYUB854-phAE87 system, containing the
hygR cassette, to construct a specialized transducing phage [80].
Homologous recombination in BCG was predicted to eliminate the
terminal 316 nucleotides of sigH including the region encoding a
putative DNA binding motif. Southern hybridization of DraIII-
digested DNA was used to verify allelic inactivation.
To construct dominant-negative (dn) enzyme monomers, sodA
was PCR-amplified from DNA of M. tuberculosis strain H37Rv,
ligated into pCR2.1-TOPO, and propagated in E. coli TOP 10.
Site-directed mutagenesis was performed using primer overlap
extension methods [81] and codon deletion was verified by DNA
sequencing. The DH28DH76 mutant was verified to lack
superoxide dismutase (SOD) activity by its inability to complement
the growth of the SOD double-negative (sodA-, sodB-) E. coli strain
CK9C1891 [82]. The dn-sodA open reading frame was then
ligated behind DNA from a 341-bp region upstream of isocitrate
lyase (icl) from H37Rv, a macrophage-inducible promoter [83], in
an effort to not severely impair the growth of SodA-diminished
strains in vitro while reducing enzyme activity in vivo. Finally,
alleles encoding dominant-negative enzyme monomers were
ligated into shuttle plasmid or chromosomal integration vectors.
Assays of SodA quantity and activity
Immunoblotting was used to compare SodA enzyme quantity.
Bacterial lysates were adjusted to a standard A280 value, applied
to a SDS-12% PAGE gel for separation of proteins by
electrophoresis and transferred to nitrocellulose membranes and
hybridized with a 1:1000 dilution of rabbit polyclonal antisera
against recombinant SodA [84]. To measure superoxide dismutase
activity in lysates and supernatants of vaccine cultures, we
monitored the % inhibition of a superoxide anion (O2
2) - induced
reduction of a water-soluble tetrazolium (WST-1) salt to a
formazan dye by colorimetric methods (SOD Assay Kit-WST,
Dojindo Molecular Technologies, Inc., Gaithersburg, MD). One
unit was defined as the amount of SodA that inhibited color
development at 440 nm by 50%.
Mice and Infections
Experiments in mice were approved by the Vanderbilt
Institutional Animal Care and Use Committee and conform to
regulatory standards for research involving vertebrate animals.
Female C57Bl/6 mice and Balb/c mice aged 5–6 weeks were
purchased from Jackson Laboratories (Bar Harbor, ME). To assess
persistence of the vaccine strain in vivo, mice were inoculated
retro-orbitally with approximately 5610
6 CFU. To assess immune
responses, mice were vaccinated subcutaneously or retro-orbitally
with sterile broth media or with preparations of BCG or 3dBCG
(BCGDsecA2DsigHdnSodA) in broth media at 5610
5 CFU. In
order to eliminate the vaccine strain before a mycobacterial
challenge, mice were treated with isoniazid and rifampin by
adding 100 mg/liter of each antibiotic to drinking water [85].
After 30 days on this regimen, mice were then rested for at least
two weeks before intravenous challenge (retro-orbital or tail-vein)
with 2610
7 CFU of BCG Tice.
Gene expression analysis
C57Bl/6 mice, six per group, were injected retro-orbitally with
1.5610
7 CFU of BCG, 3dBCG, or phosphate-buffered saline
(control). Mice were euthanized 72 hours later and the spleens
were harvested and immersed in liquid nitrogen. To recover total
cellular RNA, each spleen was homogenized with a mortar and
pestle in the presence of liquid nitrogen. The homogenized tissue
was extracted with Trizol (Gibco/Invitrogen, Carlsbad, CA)
followed by a chloroform extraction and isopropanol precipitation.
The pellet was resuspended in DNase/RNase free water (Gibco/
Invitrogen, Carlsbad, CA) and the sample was DNase-treated
(Promega, Madison, WI) for 30 minutes at 37uC. Total cellular
RNA was further purified with a Qiagen RNeasy column
purification system (Qiagen, Valencia, CA), quantitated with a
spectrophotometer, and normalized. cDNA was prepared from
each RNA sample with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) and
analyzed with Taqman primer-probe pairs (Applied Biosystems)
on an Applied Biosystems 7900HT Real-Time PCR system.
Measurement of Immune Reponses
To obtain lymphocytes for measurement of immune responses
after vaccination or challenge, mice were euthanized and
splenocytes were isolated and suspended in RPMI, enumerated,
and three million cells were used for each stimulation condition.
Synthetic peptides TB10.474-88 - ST15, a CD4 epitope
29 and
TB10.3/10.420-28 - GL9, a CD8 epitope
30 (Genemed Synthesis
Inc, San Antonio, TX) and BCG-infected bone-marrow derived
macrophages (BMDMs) were used as stimulants. BMDMs were
derived from femur bone marrow stem cells which were cultured
for 5 days in petri-dishes in DMEM medium containing 10% fetal
calf serum and 20% L-929 conditioned medium. Three days
before harvesting splenocytes, the BMDMs were transferred to 24-
well plates at 1 million cells per well, and infected the next day
with 5:1 MOI BCG Tice in the presence of 20 ng/ml IFN-c for
4 hours. Paired wells of BMDMs were similarly treated with IFN-c
but left uninfected. Forty-eight hours after infection of BMDMs, 3
million harvested splenocytes were re-stimulated on uninfected
and BCG-infected BMDMs for 20 hours, the last 18 hours in the
presence of brefeldin A. For measurement of cytokine responses to
peptide, harvested splenocytes were stimulated with or without
peptides for 6 hours, the last 4 hours in the presence of brefeldin
A. Cytokine production was assessed by intracellular cytokine
staining and flow cytometry.
Intracellular cytokine staining and flow cytometry
Stimulated splenocytes were stained sequentially with live/dead
fixable dead cell stain kit - violet fluorescent reactive dye (Invitrogen
Molecular Probes, Carlsbad, CA) and a cocktail of surface
antibodies - anti -CD3 APC-Cy7, -CD4 PE-Texas Red, and -
CD8 Pacific Orange (Invitrogen), fixed and permeabilized with
cytofix/cytoperm solution and stained with anti -IFN-c PE-Cy7, -
TNF-a FITC, and –IL-2 PE (all from BD biosciences, San Jose, CA
unless otherwise indicated) and approximately 1,000,000 events
within the lymphocyte gate were acquired using a FACSAria and
analyzed with FacsDIVA software (BDbiosciences, San Jose, CA).
The total number of cytokine+ CD4+ and CD8+ T cells per whole
spleen was calculated from the products of the total number of
splenocytes multiplied by the proportion of cytokine+ CD4+ and
CD8+ T cells under each stimulation condition. Antigen-specific
cytokine+ T cells were calculated as the difference between
cytokine+ cells from the unstimulated and stimulated conditions.
Statistics
The planned comparison in each experiment was between the
immune response to BCG and the immune response to 3dBCG.
Unless otherwise indicated, these comparisons were performed
using the Mann-Whitney determination for a non-parametric
BCG Antioxidants Foil Immunity
PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5531distribution, two-tailed, and a P value of less than 0.05 was
considered significant. Secondary comparisons involved the
responses of each vaccinated group of mice to the responses of
unvaccinated mice. To compare the medians of all three groups
we used the Kruskal-Wallis non-parametric test and the P values
for the significance of the variance of the three medians are noted
in the Figure legends. Comparisons between the immune
responses in a vaccinated group and the unvaccinated group were
further analyzed using the Mann-Whitney test, two-tailed, and a P
value of less than 0.05 was considered significant. Correlation
coefficients were calculated using non-parametric Spearman
calculations. Statistical analyses were performed using Prism 5.0
software (GraphPad) and only significant (P,0.05) or close to
significant (P,0.1) values are indicated.
Supporting Information
Table S1 Tools for genetic manipulations and bacterial strains
Found at: doi:10.1371/journal.pone.0005531.s001 (0.05 MB
DOC)
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